News
Endometriosis: Why it takes an average of 8 Years to diagnose — and how to get answers faster

Article produced in association with Spital Clinic
Around 1.5 million women in the UK are living with endometriosis — and behind that number is a shared experience that rarely makes headlines.
According to NHS guidance on endometriosis, it is one of the most common gynaecological conditions in the country. And yet for most of the women it affects, getting a diagnosis took years.
The path to that diagnosis is rarely straightforward. It is long, often lonely, and filled with appointments where very real pain is explained away or missed entirely.
The Scale of the Diagnosis Delay
The Endometriosis UK 2024 Impact Report, drawn from responses by 4,371 women with confirmed endometriosis, puts the average time from first experiencing symptoms to receiving a diagnosis at 8 years and 10 months.
Despite growing awareness and repeated calls from clinicians for earlier investigation, that figure has barely shifted in a decade.
The numbers behind that average are striking.
The same report found that 47 per cent of those women had visited their GP ten or more times before getting a diagnosis, and 78 per cent said they felt dismissed when they first raised their symptoms — up from 69 per cent in the previous survey.
That isn’t a rounding error. It is the lived reality of most women with endometriosis.
Endometriosis happens when tissue similar to the uterine lining grows outside the uterus — on the ovaries, fallopian tubes, bowel, bladder and beyond.
Because it responds to the same hormonal cycle as the uterus, it causes recurring inflammation and scarring that cannot resolve on its own. The longer it goes undiagnosed, the more opportunity there is for it to progress.
Why Diagnosis Takes So Long
Part of the problem is that there is no simple test for endometriosis. Its symptoms — painful periods, chronic pelvic pain, pain during sex, bowel and bladder problems, and persistent fatigue — overlap with conditions that GPs see far more often.
IBS and painful periods are among the most frequent misdiagnoses before endometriosis is finally considered.
There is no blood test that confirms it.
NICE guidance acknowledges something that many women already know from experience: there is a long-standing tendency — both culturally and in clinical practice — to treat severe period pain as a normal part of female life.
When pain that disrupts daily function is met with reassurance rather than investigation, the referral that might eventually lead to a diagnosis simply does not happen.
That is where much of the delay originates.
For women whose symptoms have been raised repeatedly without investigation, a specialist gynaecological assessment — through NHS referral or through a private gynaecology consultation — tends to move things forward more quickly than further appointments at GP level.
What NICE NG73 Now Recommends
In November 2024, NICE NG73 — the updated endometriosis guideline — set out a clearer diagnostic pathway: defined criteria for when to investigate, when to refer, and what tests should happen first.
The guideline recommends transvaginal ultrasound as part of the initial investigation for suspected endometriosis.
Crucially — and this is worth knowing — a normal scan does not rule out endometriosis.
Many women are told their results were clear and assume that means the matter is settled. It does not.
A scan creates objective evidence that strengthens the case for specialist referral — something a physical examination alone often cannot do.
It can be arranged through an NHS referral or through a private transvaginal ultrasound, and specialist assessment is recommended where symptoms continue regardless of what the scan shows.
A normal scan is not a closed door.
The definitive test for endometriosis remains laparoscopy — a keyhole surgical procedure under general anaesthetic that allows a surgeon to see endometrial deposits directly and, where possible, treat them at the same time.
NG73 supports laparoscopy as the appropriate next step when non-invasive assessment does not provide a clear answer. Knowing that this option exists — and that it is appropriate to ask for it — makes a real difference.
What to Do if Your Symptoms Are Not Being Investigated
The most useful thing to do right now is start documenting. Write down dates, severity, how your symptoms relate to your cycle, and the specific ways they are affecting your life — across at least two or three full cycles.
A written record is far harder to dismiss than a verbal account given at a single appointment.
A symptom diary is the single most useful document a woman can bring to a GP appointment.
When you ask for a referral, be specific — ask for a gynaecologist with a specialist interest in endometriosis, not a general gynaecology appointment.
Under NHS England’s patient choice framework, you have the right to request referral to a named provider, including specialist endometriosis centres.
If a GP declines to refer you despite a persistent symptom history, requesting a second opinion from a colleague within the same practice is a reasonable and available step.
Endometriosis affects around 1 in 10 women of reproductive age, according to NHS guidance. That is not a rare condition — and yet the gap between how common it is and how promptly it gets diagnosed remains enormous.
NICE NG73 sets a clearer standard for what investigation should look like, but guidelines change slowly and practice can lag behind.
The women who tend to move through the system fastest are the ones who know what they are entitled to ask for: a transvaginal ultrasound, onward specialist referral, and the understanding that a normal scan is not the end of the road.
If this applies to you, book a consultation with a consultant gynaecologist to begin a structured assessment.
This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment. Clinical guidance referenced reflects published NHS and NICE standards as at March 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article. This piece was produced in association with Spital Clinic, which provided background clinical information for editorial purposes. Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.
Hormonal health
Study links small bowel microbiome differences to women’s health
Menopause
Cancer drug could tackle osteoporosis menopause weight gain

An experimental cancer drug reduced bone loss and body fat in mice modelling post-menopausal changes, early research suggests.
The compound, CADD522, appeared to strengthen bones and help the animals stay leaner after surgery designed to mimic hormonal changes seen after menopause.
The treatment remains at an early experimental stage and has so far only been tested in animals.
The study, led by the University of East Anglia, investigated CADD522, which was originally developed to block a protein involved in the growth and spread of several cancers.
Mice treated with the compound for eight weeks showed significant improvements in bone health. Scans found increased bone volume and better preservation of the honeycomb-like structures inside bones that are crucial for strength and resilience.
Blood tests suggested the treatment stimulated new bone growth without interfering with the body’s normal process of breaking down and rebuilding bone.
Dr Darrell Green, lead researcher from UEA’s Norwich Medical School, said: “Osteoporosis affects around one in three women over the age of 50, leaving sufferers vulnerable to painful fractures that can seriously impact quality of life.
“Current treatments exist, but many are plagued by side effects, safety concerns or inconvenient dosing schedules that make long-term use difficult.”
The researchers also found that mice receiving CADD522 weighed less than untreated mice despite eating the same amount of food.
They had less body fat and fewer fat deposits in their bone marrow, a process commonly seen after menopause and linked to declining bone health.
The team also examined brain tissue and found that the drug appeared to reverse several menopause-related changes in fatty acids.
Levels of omega-3 fats including DHA remained largely intact, while several other lipid abnormalities shifted back towards healthier patterns.
Green said: “We didn’t directly test for memory or thinking ability, but our work raises questions about whether this drug could one day help address wider menopause-related health problems.”
Safety experiments in mice, rats and dogs found that CADD522 could be taken orally and was well tolerated.
The compound also appeared to be metabolised more slowly in human tissue than in rodents, potentially improving its performance in people.
“This is still in the early stages and has so far only been tested in animals but we hope that the benefits will translate to humans to ultimately reduce fracture rates,” added Green.
The research was led by UEA in collaboration with the University of Maryland, the Scintillon Research Institute in San Diego and the University of Stirling.
Safety testing was funded by The Sir William Coxen Trust as part of the development of CADD522 as a childhood cancer treatment.
Fertility
Weight loss surgery improves menstrual health and PMOS symptoms, study finds

Weight loss surgery was linked to more regular periods and fewer polyendocrine metabolic ovarian syndrome (PMOS) symptoms in women aged 18 to 45 living with obesity in a recent study.
The researchers recommend that women undergoing the procedure have access to preconception care and reproductive counselling to support their reproductive health.
Researchers at the University of Surrey analysed data over 24 months from 84 women who underwent bariatric surgery and 18 women living with obesity who did not have surgery.
Of those who underwent surgery, 49 had gastric bypass procedures and 35 had gastric sleeve surgery.
Women who underwent metabolic bariatric surgery lost more than 30kg on average at 12 and 24 months after the procedure.
Among women with polycystic ovaries, the condition persisted in only 10 per cent after 24 months.
Women also reported a resolution of clinical hirsutism, or excess body hair, by 12 months.
Women who had previously experienced irregular periods reported more regular menstrual cycles after surgery.
Professor Martin Whyte, co-author of the study and professor of metabolic medicine at the University of Surrey, said: “A large proportion of those undergoing bariatric surgery are women of reproductive age, who may be planning a pregnancy in the coming years.
“So much remains unknown about the impact of this type of surgery on women who are planning to have children.
“This raises the question of when the ideal time after surgery is to conceive.”
Women have a higher prevalence of obesity than men, with 57 per cent of women in the UK classified as overweight and 27 per cent living with obesity, which can affect fertility and the health of an unborn baby.
The researchers said 17 women had healthy pregnancies following surgery.
Although this was not specifically examined in the study, no difference in birth weight was observed between babies conceived within or after the first year.
Dr Kathryn Hart, co-author of the study and associate professor in nutrition and dietetics at the University of Surrey, said: “What we have found is that bariatric surgery positively affects the reproductive health of women living with obesity and can improve the likelihood of them having a healthy pregnancy after surgery.
“Dysregulated hormone levels, irregular periods and conditions such as polycystic ovaries are affected by obesity.
“By reducing this, what we have seen is that it can lead to improvements without the need for medication.
“We would suggest that clinicians consider medical intervention for obesity to treat irregularities in the menstrual cycle and issues with fertility.”
Hormonal health2 weeks agoMajor UK study could be a ‘game-changer’ for heavy periods and endometriosis
Entrepreneur7 days agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Pregnancy2 weeks agoOne week left to apply: W Accelerate with Merck KGaA and M Ventures
Pregnancy1 week agoUK study aims to transform maternity care for high-risk pregnancies
Menopause2 weeks agoQuarter of women miss work due to menstual symptoms, survey finds
Mental health2 weeks agoPMDD after SSRIs or hormones: Why the brain may be the missing treatment target
Diagnosis2 weeks agoArk Surgical secures further institutional backing to accelerate US expansion
Menopause5 days agoMenopause hormone treatment may ease brain fog, study suggests













4 Comments